<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/FD320FB3-A362-49C4-ADA3-8B5FF3A5F88A"><gtr:id>FD320FB3-A362-49C4-ADA3-8B5FF3A5F88A</gtr:id><gtr:name>MRC Functional Genomics Unit</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/FD320FB3-A362-49C4-ADA3-8B5FF3A5F88A"><gtr:id>FD320FB3-A362-49C4-ADA3-8B5FF3A5F88A</gtr:id><gtr:name>MRC Functional Genomics Unit</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7727C1A9-7267-4E5B-9806-FD60578BE66D"><gtr:id>7727C1A9-7267-4E5B-9806-FD60578BE66D</gtr:id><gtr:firstName>Anastasios</gtr:firstName><gtr:surname>Karadimitris</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/ADDC07ED-6C82-484C-A35D-3EF052EB38A1"><gtr:id>ADDC07ED-6C82-484C-A35D-3EF052EB38A1</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Mark</gtr:otherNames><gtr:surname>Layton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0802401"><gtr:id>1FAE519D-AEFA-45DA-BF7F-C0E6FAEF3FDF</gtr:id><gtr:title>Transcriptional control of house keeping genes by Sp1 and histone acetylation: molecular mechanisms and therapeutic potential</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0802401</gtr:grantReference><gtr:abstractText>We have recently described a disease caused by a defect in a gene required for the formation of a molecule called GPI. Affected children suffer from life-threatening blood clots and severe epilepsy. 
We found that in the DNA of these patients, attachment of a molecule called acetyl group, required for the proper function of genes, was very low; and that a drug called butyrate could restore attachment of the acetyl groups and thus restore the function of the gene. Furthermore, treatment of a patient with butyrate led to complete cessation of lifelong and uncontrollable seizures.

With this work we would like to understand better the role of these acetyl groups in causing disease and how butyrate exerts its beneficial effect. We will also explore whether butyrate can benefit patients with other inherited and often lethal disorders for which no specific treatment exists.</gtr:abstractText><gtr:technicalSummary>Sp1 is a general transcription factor (TF) that can modulate histone acetylation and thus transcription by recruiting to the promoter histone acetyltransferases (HAT) and deacetylases (HDAC). For some genes, enhanced transcription in response to HDAC inhibition requires Sp1 binding to the promoter. We have shown that a single nucleotide substitution at the promoter of PIGM, encoding a mannosyltransferase required for glycosylphosphatidylinositol (GPI) synthesis, results in Sp1 binding disruption, histone hypoacetylation, reduced transcription and eventually inherited GPI deficiency (IGD). HDAC inhibitor butyrate restored acetylation in a Sp1-dependent manner, PIGM transcription, GPI biosynthesis and was of great therapeutic value in a patient with IGD. 
The aim of this project is to dissect the transcriptional regulation of house-keeping genes, as exemplified by PIGM, by Sp1-dependent histone acetylation and explore whether its butyrate-mediated modulation could be of therapeutic potential in inherited disorders of glycolysis.
For this purpose, using human PIGM and glycolytic enzyme deficient cell lines and a murine knock-in model of inherited GPI deficiency the relative roles of Sp1, HAT/HDAC and other TF such as GATA-1 in regulating transcription of PIGM and genes of the glycolytic pathway at baseline and in response to HDAC inhibitors will be studied.</gtr:technicalSummary><gtr:fund><gtr:end>2013-01-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>501206</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC Functional Genomics Unit</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Computational Genomics Analysis and Training Programme (CGAT)</gtr:department><gtr:description>Collaboration with the MRC CGAT Programme</gtr:description><gtr:id>E8FCC4DC-E00D-4001-BA20-F80158F39AD7</gtr:id><gtr:impact>work ongoing</gtr:impact><gtr:partnerContribution>Bioinformatics Analysis and design</gtr:partnerContribution><gtr:piContribution>Generation of 4C libraries to study long range genomic interactions of the mutant PIGM promoter</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Transcriptional deregualtion in multiple myeloma</gtr:description><gtr:end>2019-08-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>C58A452C-63B4-4CBF-9B5D-B7D2EB1E8E44</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>293FRT/HeLa FRT- PIGMpromoter-luciferase and \EGFP collection cell lines. These reporter cell lines are designed to help assess the promoter and the mutant (several) promoter activity in vivo both using luciferase assay and single cell analysis (EGFP).</gtr:description><gtr:id>6976EF2A-5A2F-480B-9742-61C355D2900F</gtr:id><gtr:impact>We are starting to analyse the effect of the GATA-1 transfected into the cell lines. In the future we plan to assess the silencing of different components af the transcriptional machinery.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>293FRT/HeLaFRT- PIGMpromoter-luciferase and \EGFP collection</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have develop a protocol for primary cell erythroid differentiation in vitro from PBMC (peripheral blood mononuclear cells) and cord blood CD34+,</gtr:description><gtr:id>89A0869D-00AC-49DB-981E-39FA9F4850A7</gtr:id><gtr:impact>We are assessing the effect of HDACi (HDAC inhibitors) in the glycolytic enzymes activity both, in cell lines and in the in vitro generated erythroid cells</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Protocol for primary cell erythroid differentiation in vitro</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>ChIP-re ChIP: Immunoprecipitation technique that allows the establishment of interactions between proteins and/or protein complexes with specific DNA regions in vivo.
MNase nucleosome mapping: molecular technique that allows the detection of the presence of nucleosome in specific regions of DNA in vivo. It is based in the protection that the nucleosomes provide to the MNase treatment.

3C, 4C and e4C (Chromosome conformation capture
and derivates): molecular technique that allows the study the 3D chromosome organization in vivo</gtr:description><gtr:id>DFC91D46-6596-4B61-97E2-C6771B412719</gtr:id><gtr:impact>The project has just started on September 2009. All this techniques are the basic to develop the objectives of the study. After the establishment they have allow us to provide important insides on the molecular mechanisms of the transcriptional control of the PIGM promoter (a model housekeeping gene), some of them unpredicted and potentially novel .</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ChIP and re-ChIP analysis, MNase nucleosome mapping, 3C and e4C technology</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Lentiviral infection with shRNA vectors is an efficient way of introducing shRNA in difficult to transfect cells (B cell lines, primary cells). We have introduce EGFP /or DsRED genes in the plasmids, to allow the sort of infected cells to have pure populations</gtr:description><gtr:id>E64721B3-DD09-41E8-B479-598C5104FBD7</gtr:id><gtr:impact>shRNA lentiviral vectors are going to be used to study the role of GATA-1, Sp1 and other components of the general transcriptional machinery in regulating the transcription of PIGM promoter (WT and mutant) in patients b-cell lines and other cell lines (erythroid, 293FRT and HeLaFRT)</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Lentiviral set of shRNA vectors, Retroviral for Sp1 and dominant negative Sp1 overexpression</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/42CB3484-CF3D-4787-A957-486BC66683BF"><gtr:id>42CB3484-CF3D-4787-A957-486BC66683BF</gtr:id><gtr:title>Cell-type-specific transcriptional regulation of PIGM underpins the divergent hematologic phenotype in inherited GPl deficiency.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ad132f288ab3a9e158b8d87fb3db484c"><gtr:id>ad132f288ab3a9e158b8d87fb3db484c</gtr:id><gtr:otherNames>Costa JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C69D6365-6A67-4256-98EA-3428FAA6E29A"><gtr:id>C69D6365-6A67-4256-98EA-3428FAA6E29A</gtr:id><gtr:title>Transcriptional and epigenetic basis for restoration of G6PD enzymatic activity in human G6PD-deficient cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8cb31d2e26049f6f3b6d71f441fa4fc1"><gtr:id>8cb31d2e26049f6f3b6d71f441fa4fc1</gtr:id><gtr:otherNames>Makarona K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B0EF84C6-4019-47D8-A924-8888F46C4FC5"><gtr:id>B0EF84C6-4019-47D8-A924-8888F46C4FC5</gtr:id><gtr:title>Mechanism of Polycomb recruitment to CpG islands revealed by inherited disease-associated mutation.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/49bbf15ae91e579d7dd8da771bc34e24"><gtr:id>49bbf15ae91e579d7dd8da771bc34e24</gtr:id><gtr:otherNames>Caputo VS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802401</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>